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the available photon energies in our TrueBeam: 6MV, 15MV, 
6MV FFF and 10MV FFF. Geometrical checks were measured 
only for the 6MV beam. 
 
Results: In all our measurements we found that the results 
were within the established tolerances. The value of the 
isocenter’s size is, in our case, 0.27 mm, very close to that 
obtained by Clivio et al. for the same energy, 0.34 mm. The 
values of the 6MV beam center shift, MV imager projection 
offset and absolute gantry positioning are the same that the 
ones obtained in the mentioned study: 0.04 mm, 0.17 mm 
and -0.09° respectively. For that same energy the offset of 
the collimator rotation is, in our case, 0.15°, while the one 
reported in the study is 0.17°, and the kV imager projection 
offset, 0.24 mm versus 0.32 mm. The output change in our 
TrueBeam varies from -0.58% for the 10MV FFF beam to -
0.50% for the 6MV beam. In the study these values range from 
0.06% for their 15 MV beam to 0.24% for their 6MV FFF beam. 
 
Conclusion: Our TrueBeam MPC results were compared with 
those obtained by Clivio et al. at their institution. They show 
great agreement with those reported in their study. We have 
established MPC tool measurements as part of our routine 
daily QA. 
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Purpose or Objective: To evaluate the dosimetric and 
optimization algorithm accuracy of a newly released version 
13.5 of the Eclipse treatment planning system (TPS) prior to 
upgrade, utilizing the recently published AAPM Medical 
Physics Practice Guideline (MPPG), “Commissioning and QA of 
treatment planning dose calculations”. 
 
Material and Method: Eclipse V13.5 includes many novel 
features, such as contouring tool enhancements, streamlined 
4D CT contouring, new physical materials for the AcurosXB 
(AXB) dose algorithm, and faster optimization engines. MPPG 
phantom tests were performed to validate both static and 
dynamic beams in both homo- and hetero- generous material. 
Additionally, 54 patient plans were re-calculated in V13.5 
with the same beam parameters, monitor units, and dose 
algorithms in order to examine algorithm difference. A dose-
difference plan was created by subtracting the dose 
calculated in V13.5 from V11 and evaluated in 3D dose 
display. Those re-calculated patient plans included a variety 
of treatment sites, energies, and techniques. However, the 
new Photon Optimizer (PO) algorithm was developed in V13.5 
to replace the previous Dose Volume Optimizer (DVO) in IMRT 
and Progressive Resolution Optimizer (PRO) in VMAT. In order 
to compare the PO and DVO/PRO optimizers, 25 IMRT/VMAT 
clinical plans were re-optimized with PO using the same 
objectives, prescriptions, and number of iterations. The plan 
quality and optimization time were examined. 
 
Results: Dose differences for all clinical cases and MPPG 
phantom tests in-field and in homogeneous areas, were 
within 1% and 3% for photon and electron plans, respectively. 
Although the beam models were not re-commissioned in 
V13.5, the dosimetric leaf gap (DLG) value was modified and 
the new physical material was added in AXB; as a result the 
dose differences correspond to differences in the dose 
algorithms. Therefore, at field edges and heterogeneity 
interfaces, maximum dose differences increased to 3% and 6% 
for photons and electrons, respectively. Dose calculated 
using AXB was found to be 3% less at the lung interface and 
inside the lung in V13.5 compared to dose calculated in V11, 
but no dose difference calculated using AAA was seen. PO 
could optimize plans 20-30% faster than DVO/PRO. For most 
cases, no significant difference in plan quality was noted. 
However, lung SBRT cases with PO showed a reduction in MUs 
and slightly improved dose conformity. 
 
 
 
 
Conclusion: Commissioning and QA of new TPS version is 
essential prior to clinical release. The tests suggested by 
MPPG provide an excellent framework for this work, 
particularly when combined with additional clinical cases. 
Dose differences noted were chiefly located at beam edges, 
possibly due to modified DLG values, and in heterogeneous 
materials and interfaces using AXB, potentially due to 
differences in material specification. The PO improved 
optimization efficiency in all cases and MU economy and dose 
conformity in some SBRTs, with no reduction in plan quality. 
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